Zenas BioPharma, Inc. (ZBIO)
27.48
-2.16
(-7.27%)
USD |
NASDAQ |
Sep 24, 16:00
27.48
0.00 (0.00%)
After-Hours: 19:59
Zenas BioPharma Enterprise Value : 1.623B for Sept. 23, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 23, 2026 | 1.623B |
| September 22, 2026 | 1.840B |
| September 21, 2026 | 1.808B |
| September 18, 2026 | 1.741B |
| September 17, 2026 | 1.771B |
| September 16, 2026 | 1.793B |
| September 15, 2026 | 1.769B |
| September 14, 2026 | 1.767B |
| September 11, 2026 | 1.717B |
| September 10, 2026 | 1.716B |
| September 09, 2026 | 1.791B |
| September 08, 2026 | 1.840B |
| September 04, 2026 | 1.829B |
| September 03, 2026 | 1.831B |
| September 02, 2026 | 1.845B |
| September 01, 2026 | 1.772B |
| August 31, 2026 | 1.793B |
| August 28, 2026 | 1.727B |
| August 27, 2026 | 1.812B |
| August 26, 2026 | 1.839B |
| August 25, 2026 | 1.885B |
| August 24, 2026 | 1.751B |
| August 21, 2026 | 1.791B |
| August 20, 2026 | 1.749B |
| August 19, 2026 | 1.726B |
| Date | Value |
|---|---|
| August 18, 2026 | 1.767B |
| August 17, 2026 | 1.678B |
| August 14, 2026 | 1.615B |
| August 13, 2026 | 1.596B |
| August 12, 2026 | 1.728B |
| August 11, 2026 | 1.801B |
| August 10, 2026 | 1.772B |
| August 07, 2026 | 1.800B |
| August 06, 2026 | 1.784B |
| August 05, 2026 | 1.764B |
| August 04, 2026 | 1.736B |
| August 03, 2026 | 1.718B |
| July 31, 2026 | 1.738B |
| July 30, 2026 | 1.790B |
| July 29, 2026 | 1.715B |
| July 28, 2026 | 1.791B |
| July 27, 2026 | 1.825B |
| July 24, 2026 | 1.671B |
| July 23, 2026 | 1.709B |
| July 22, 2026 | 1.741B |
| July 21, 2026 | 1.796B |
| July 20, 2026 | 1.691B |
| July 17, 2026 | 1.617B |
| July 16, 2026 | 1.535B |
| July 15, 2026 | 1.609B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.495B |
| Alnylam Pharmaceuticals, Inc. | 32.65B |
| Anika Therapeutics, Inc. | 259.52M |
| Savara, Inc. | 884.37M |
| Vericel Corp. | 1.917B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -111.46M |
| Revenue (Quarterly) | 1.00M |
| Total Expenses (Quarterly) | 112.46M |
| EPS Diluted (Quarterly) | -1.766 |
| Gross Profit Margin (Quarterly) | 99.60% |
| Profit Margin (Quarterly) | -11.15K% |
| Earnings Yield | -35.00% |
| Normalized Earnings Yield | -24.35 |